HIV and liver disease forum: Conference proceedings
Article first published online: 30 MAY 2007
Copyright © 2007 American Association for the Study of Liver Diseases
Volume 45, Issue 6, pages 1566–1577, June 2007
How to Cite
Sherman, K. E., Peters, M. and Koziel, M. J. (2007), HIV and liver disease forum: Conference proceedings. Hepatology, 45: 1566–1577. doi: 10.1002/hep.21722
The meeting participants included the following individuals: The chairman was Kenneth E. Sherman, M.D., Ph.D., University of Cincinnati. The cochairs were Marion Peters, M.D., University of California, San Francisco; Michael Polis, M.D., National Institutes of Health; and Vincent Soriano, M.D., Hospital Carlos III. The speakers (invited and selected) were Miriam Alter, Ph.D., University of Texas Medical Branch at Galveston; Pablo Barreiro, M.D., Ph.D., Hospital Carlos III; Yves Benhamou, M.D., Ph.D., Department of Hepatology and Gastroenterology of Pitié-Salpêtriè Hospital, Paris, France; Edmund Bini, M.D., M.P.H., New York University School of Medicine; Jason Blackard, Ph.D., University of Cincinnati; Norbert Bräu, M.D., M.B.A., VA Medical Center; Susan Brobst, M.D., Ph.D., National Institute of Allergy and Infectious Diseases, National Institutes of Health; Nathaniel Brown, M.D., Idenix Pharmaceuticals, Inc.; Raymond Chung, M.D., Harvard Medical School; Carmen de Mendoza, Ph.D., Hospital Carlos III; Brian Edlin, M.D., Weill Medical College of Cornell University; Judith Feinberg, M.D., University of Cincinnati College of Medicine; Mariana Gerschenson, Ph.D., John A. Burns School of Medicine; Margaret Koziel, M.D., Beth Israel Deaconess Medical Center; Barbara McGovern, M.D., Tufts University School of Medicine/Lemuel Shattuck Hospital; Jeffrey Murray, M.D., Food and Drug Administration; David Oldach, M.D., University of Maryland Biotechnology Institute; Alan Perelson, Ph.D., Los Alamos National Laboratory; Marion Peters, M.D., University of California at San Francisco; Michael Alan Polis, M.D., M.P.H., National Institute of Allergy and Infectious Diseases, National Institutes of Health; Peter Revill, Ph.D., Victorian Infectious Diseases Reference Laboratory, Australia; David Rimland, M.D., VA Medical Center; Mohammed Tarek Shata, M.D., Ph.D., University of Cincinnati; Kenneth Sherman, M.D., Ph.D., University of Cincinnati; Norah Shire, M.P.H., University of Cincinnati; Vincent Soriano, M.D., Ph.D., Hospital Carlos III; Richard Sterling, M.D., Virginia Commonwealth University; Peter Stock, M.D., Ph.D., University of California at San Francisco; Daniel Suzman, A.B., National Institute of Allergy and Infectious Diseases, National Institutes of Health; Phyllis Tien, M.D., University of California at San Francisco/VA Medical Center; and Stacey Vlahakis, M.D., Mayo Clinic.
Potential conflict of interest: Nothing to report.
- Issue published online: 30 MAY 2007
- Article first published online: 30 MAY 2007
- Manuscript Accepted: 8 MAR 2007
- Manuscript Received: 15 FEB 2007
- Gilead Sciences
- Abbott Laboratories
- Idenix Pharmaceuticals (who provided financial support for the meeting)
- National Institutes of Health through the National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute on Drug Abuse. Grant Number: R13 grant (AI071925)
- 3World Health Organization. Available at: http://www.who.int/topics/hiv_infections/en/. Accessed March 20, 2007.
- 8The impact of alcohol and HIV on antigen-specific immune responses in hepatitis C. J Infect Dis. In press., , , , , , et al.
- 36Treating opportunistic infections among HIV-exposed and infected children. MMWR Recomm Rep 2004; 53: 1–112., , , , .
- 47Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. Clin Infect Dis 2005; 41: 1186–1195., , , , , , et al.
- 55Unexpected significant liver disease among HIV/HCV coinfected persons with minimal fibrosis on initial liver biopsy. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston, MA., , , , .
- 59Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55: 1–17; quiz CE11–CE14., , , , , , et al.
- 61Dept of Health and Human Services, Office of AIDS Research Advisory Council. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://AIDSinfo.nih.gov. Accessed March 20, 2007.
- 69The PRESCO trial: impact of higher ribavirin doses and longer duration of therapy with peginterferon alfa-2a plus ribavirin in HIV-infected patients with chronic hepatitis C. Paper presented at: AASLD, 2006; Boston, MA., , , , , , et al.
- 73The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). J Hepatol 1994; 21: 646–655., , , , , , et al.
- 93Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179–183., , , , , , et al.Direct Link: